A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis

被引:1
|
作者
Chen DongNi [1 ,2 ]
Fan Li [1 ,2 ]
Wu YuXi [1 ,2 ]
Zhou Qian [3 ]
Chen Wei
Yu XueQing [1 ,2 ,4 ]
机构
[1] Clinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
[2] Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
[3] Guangdong Medical University, Zhanjiang, Guangdong 524023, China
[4] Key Laboratory of Nephrology, Ministry of Health and Guangdong Province, Guangzhou, Guangdong 510080, China
关键词
Biopsy; Lupus Nephritis; Nomogram; Predictive Value of Tests; Risk Factors;
D O I
暂无
中图分类号
R593.242 [];
学科分类号
摘要
Background: Lupus nephritis (LN) is classified by renal biopsy into proliferative and nonproliferative forms, with distinct prognoses, but renal biopsy is not available for every LN patient. The present study aimed to establish an alternate tool by building a predictive model to evaluate the probability of proliferative LN.Methods: In this retrospective cohort with biopsy-proven LN, 382 patients in development cohort, 193 in internal validation cohort, and 164 newly diagnosed patients in external validation cohort were selected. Logistic regression model was established, and the concordance statistics (C-statistics), Akaike information criterion (AIC), integrated discrimination improvement, Hosmer-Lemeshow test, and net reclassification improvement were calculated to evaluate the performance and validation of models.Results: The prevalence of proliferative LN was 77.7% in the whole cohort. A model, including age, gender, systolic blood pressure, hemoglobin, proteinuria, hematuria, and serum C3, performed well on good-of-fit and discrimination in the development chohort to predict the risk of proliferative LN (291 for AIC and 0.84 for C-statistics). In the internal and external validation cohorts, this model showed good capability for discrimination and calibration (0.84 and 0.82 for C-statistics, and 0.99 and 0.75 forPvalues, respectively).Conclusion: This study developed and validated a model including demographic and clinical indices to evaluate the probability of presenting proliferative LN to guide therapeutic decisions and outcomes.
引用
收藏
页码:1275 / 1281
页数:7
相关论文
共 50 条
  • [41] Treatment of proliferative lupus nephritis - A critical approach
    Buhaescu, Irina
    Covic, Adrian
    Deray, Gilbert
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2007, 36 (04) : 224 - 237
  • [42] Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?
    Grootscholten, C
    Berden, JHM
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (06) : 1465 - 1469
  • [43] Steroid Use in Pediatric Proliferative Lupus Nephritis
    Chalhoub, Nathalie
    Deng, Jianghong
    Ruth, Natasha M.
    Ardoin, Stacy P.
    Gilbert, Mileka
    Hennard, Theresa
    Hiraki, Linda
    Jensen, Paul T.
    Knight, Andrea M.
    Kunder, Rebecca
    Lewandowski, Laura
    Lim, Siok Hoon Lily
    Merritt, Angela
    Savani, Sonia Iqbal
    Son, Mary Beth
    von Scheven, Emily
    Wenderfer, Scott E.
    Brunner, Hermine I.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [44] Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
    Oh Chan Kwon
    Jung Hwan Park
    Hyeong-Cheon Park
    Seung Min Jung
    Sang-Won Lee
    Jason Jungsik Song
    Yong-Beom Park
    Min-Chan Park
    Arthritis Research & Therapy, 22
  • [45] Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
    Kwon, Oh Chan
    Park, Jung Hwan
    Park, Hyeong-Cheon
    Jung, Seung Min
    Lee, Sang-Won
    Song, Jason Jungsik
    Park, Yong-Beom
    Park, Min-Chan
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [46] NON-HISTOLOGIC FACTORS DISCRIMINATING PROLIFERATIVE LUPUS NEPHRITIS FROM MEMBRANOUS LUPUS NEPHRITIS
    Kwon, O. C.
    Park, J. H.
    Park, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 668 - 668
  • [47] Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
    Alizadeh, Madeline
    Pandian, Vishnuprabu
    Felix, Christele
    Nimoni, Andrra
    Divers, Jasmin
    Niewold, Timothy
    Blazer, Ashira
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4830 - 4831
  • [48] Clinical predictive model to estimate probability of remission in patients with lupus nephritis
    Kang, Yingxi
    Zuo, Yongdi
    He, Manrong
    Duo, Lijin
    Duo, Xiaole
    Tang, Wanxin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 110
  • [49] Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption
    Sandra Karanović Štambuk
    Ivan Padjen
    Nikolina Bašić Jukić
    Jadranka Šeparović Hanževački
    Branimir Anić
    Clinical Rheumatology, 2023, 42 : 1723 - 1725
  • [50] Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis
    Daleboudt, G. M. N.
    Broadbent, E.
    Berger, S. P.
    Kaptein, A. A.
    LUPUS, 2011, 20 (03) : 290 - 298